<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of cat scratch disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of cat scratch disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of cat scratch disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David H Spach, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 09, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cat scratch disease (CSD) is an infectious disease usually characterized by self-limited regional lymphadenopathy. The manifestations of CSD, however, can include visceral organ, neurologic, and ocular involvement [<a href="#rid1">1,2</a>]. <em>Bartonella</em> <em>henselae</em> is the etiologic agent in most cases of CSD.</p><p>The treatment of CSD will be reviewed here. The microbiology, epidemiology, and clinical features of CSD, <em>Bartonella</em> endocarditis, and other <em>Bartonella</em> infections, as well as the evaluation and management of cat bites, are discussed separately. (See  <a class="medical medical_review" href="/d/html/5532.html" rel="external">"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease"</a> and  <a class="medical medical_review" href="/d/html/2145.html" rel="external">"Endocarditis caused by Bartonella"</a> and  <a class="medical medical_review" href="/d/html/5512.html" rel="external">"Bartonella infections in people with HIV"</a> and  <a class="medical medical_review" href="/d/html/5517.html" rel="external">"Bartonella quintana infections: Clinical features, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/d/html/5516.html" rel="external">"South American bartonellosis: Oroya fever and verruga peruana"</a> and  <a class="medical medical_review" href="/d/html/7671.html" rel="external">"Animal bites (dogs, cats, and other mammals): Evaluation and management"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>We suggest antimicrobial therapy be administered to all patients with CSD.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with lymphadenitis as the only manifestation, we suggest single-drug therapy. (See <a class="local">'Lymphadenitis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those with more serious infections (eg, hepatosplenic disease, neurologic and ocular disease), we suggest combination therapy that includes <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>. (See <a class="local">'Hepatosplenic disease/fever of unknown origin'</a> below and <a class="local">'Neurologic and ocular manifestations'</a> below.)</p><p></p><p>In certain settings, such as the treatment neuroretinitis and refractory lymphadenitis, adjunctive therapies (eg, corticosteroids and/or lymph node aspiration) may be warranted. (See <a class="local">'Neuroretinitis'</a> below and <a class="local">'Adjunctive treatments'</a> below and <a class="local">'Role of corticosteroids'</a> below.)</p><p>The approach to treatment of CSD primarily derives from case reports, small series, and personal experience. In vitro susceptibility testing often does not correlate with a clinical response and should not be considered in the choice of antibiotics [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H7"><span class="h1">LYMPHADENITIS</span></p><p class="headingAnchor" id="H4276501801"><span class="h2">Whom to treat</span><span class="headingEndMark"> — </span>We suggest antimicrobial treatment for all patients with CSD who have lymphadenitis, even immunocompetent patients with mild to moderate disease. This includes patients with presumed CSD based upon epidemiologic risk factors and typical clinical manifestations. (See  <a class="medical medical_review" href="/d/html/5532.html" rel="external">"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease", section on 'Approach to diagnosis'</a>.)</p><p>Although many patients with lymphadenitis have gradual resolution of symptoms without specific antibiotic therapy [<a href="#rid3">3-5</a>], we treat patients in an effort to prevent serious complications, since up to 14 percent of patients will have dissemination of the organisms, with potential infection of the liver, spleen, eye, or central nervous system [<a href="#rid6">6-8</a>]. </p><p>In addition, available data suggest that antibiotic treatment of CSD can shorten the duration of symptoms [<a href="#rid9">9,10</a>]. In a randomized, placebo-controlled trial in 29 children and adults with CSD manifested as regional lymphadenopathy, 7 of the 14 patients who received <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> achieved an 80 percent decrease of lymph node volume in the first 30 days post-treatment compared with only 1 of 15 patients who received placebo (odds ratio 17; 95% CI 1.5 to 196) [<a href="#rid10">10</a>]. Similarly, in a large retrospective study that included 268 persons with CSD (age range 6 months to 72 years), the mean duration of illness was 2.8 weeks for the 89 patients treated with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, or <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> versus 14.5 weeks for those who were not treated or were treated with antibiotics thought to be ineffective [<a href="#rid9">9</a>]. </p><p>However, some experts do not recommend treating CSD that manifests as uncomplicated lymphangitis [<a href="#rid11">11</a>]. The major rationale for not treating is that most persons have self-resolution of the illness without complications, and the available data suggesting benefit of antimicrobial therapy are very limited.</p><p class="headingAnchor" id="H3001679124"><span class="h2">Antimicrobial regimens</span><span class="headingEndMark"> — </span>For patients with lymphadenitis, we suggest a five-day course of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>  (<a class="graphic graphic_table graphicRef118014" href="/d/graphic/118014.html" rel="external">table 1</a>). As discussed above, 7 of 14 patients who received azithromycin had a decrease of 80 percent or more in lymph node volume during a 30-day follow-up period compared with only one of fifteen placebo recipients [<a href="#rid10">10</a>]. (See <a class="local">'Whom to treat'</a> above.)</p><p>In patients intolerant to <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, we suggest a 7- to 10-day course of <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>. Specific dosing recommendations are found in the table  (<a class="graphic graphic_table graphicRef118014" href="/d/graphic/118014.html" rel="external">table 1</a>). The use of these alternative regimens for the treatment of CSD has only been evaluated in small case series [<a href="#rid9">9,12,13</a>]. For adults, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> may also be an option as an alternative agent since it has been used with apparent clinical success in immunocompetent patients [<a href="#rid14">14</a>]. </p><p>For patients with lymphadenitis that does not respond to therapy after three to four weeks, we re-evaluate the patient in an effort to find an alternative diagnosis. If CSD is still the most likely diagnosis, we repeat treatment with a five-day course of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, as dosed above, and add <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> for five days as well. </p><p class="headingAnchor" id="H175853284"><span class="h2">Adjunctive treatments</span><span class="headingEndMark"> — </span>In addition to antibiotics, adjunctive therapies may be warranted in severe or refractory cases. Needle aspiration of painful suppurative lymph nodes may hasten the relief of symptoms  (<a class="graphic graphic_picture graphicRef133125" href="/d/graphic/133125.html" rel="external">picture 1</a>). On rare occasion, we administer corticosteroids to patients with severe or persistent disease. (See <a class="local">'Role of corticosteroids'</a> below.)</p><p>Surgical drainage is generally not recommended; however, excision of the affected lymph nodes may be reasonable in select patients with infection unresponsive to a prolonged course of treatment. As an example, in one case report, surgical excision was required to achieve resolution of persistent infection in an immunocompromised patient with progressive symptoms despite approximately nine months of antimicrobial therapy [<a href="#rid15">15</a>]. Lymph node excision may also be indicated if a patient has failed to respond to treatment and the diagnosis of CSD is uncertain.</p><p class="headingAnchor" id="H8"><span class="h1">HEPATOSPLENIC DISEASE/FEVER OF UNKNOWN ORIGIN</span><span class="headingEndMark"> — </span>There are limited data to guide the management of patients with disseminated CSD. Antimicrobial therapy alone is typically sufficient; however, on rare occasion, adjunctive corticosteroids can also be administered. (See <a class="local">'Role of corticosteroids'</a> below.)</p><p class="headingAnchor" id="H3335943764"><span class="h2">Choice of regimen</span><span class="headingEndMark"> — </span>For patients with disseminated disease, such as hepatosplenic disease and fever of unknown origin, we suggest treating with <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> plus <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>. An alternative regimen is rifampin plus <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>. For adults who cannot receive rifampin, a higher dose of azithromycin alone can be administered. Specific dosing recommendations are found in the table  (<a class="graphic graphic_table graphicRef118014" href="/d/graphic/118014.html" rel="external">table 1</a>). </p><p>In one report, 19 children (aged 2 to 11 years) who had hepatosplenic CSD appeared to respond well to <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> given alone or in combination with either <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> [<a href="#rid16">16</a>]. These patients most often received rifampin at a dose of 20 mg/kg per day for 14 days. Another report described three patients with CSD who responded to intravenous gentamicin; two of the patients had extensive hepatic involvement [<a href="#rid17">17</a>]. A small case series also described successful treatment of three adults with hepatosplenic disease using a five-day course of oral <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> 500 mg daily without rifampin [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H3022959460"><span class="h2">Patient monitoring</span><span class="headingEndMark"> — </span>There are no specific markers or titers that can be followed to ensure successful treatment. We monitor the clinical response and C-reactive protein levels. In patients with severe or persistent disease, it may be reasonable to administer adjunctive corticosteroids. (See <a class="local">'Role of corticosteroids'</a> below.)</p><p>In patients with hepatosplenic disease, some providers perform follow-up abdominal imaging approximately six months after treatment to document that the lesions are regressing. However, we believe further imaging is not necessary if the patient has experienced complete clinical resolution.</p><p class="headingAnchor" id="H961766596"><span class="h1">NEUROLOGIC AND OCULAR MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with CSD can develop ocular complications (eg, neuroretinitis, Parinaud oculoglandular syndrome) and neurologic manifestations (eg, encephalopathy). (See  <a class="medical medical_review" href="/d/html/5532.html" rel="external">"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease", section on 'Clinical manifestations'</a>.)</p><p>We suggest treatment of all patients with neurologic and ocular manifestations in an effort to reduce the risk of long-term sequelae, even though some reports suggest patients may improve on their own [<a href="#rid19">19</a>]. </p><p class="headingAnchor" id="H917287427"><span class="h2">Preferred regimens</span><span class="headingEndMark"> — </span>The optimal therapy for neurologic and ocular disease is unknown. Our preferred approach is summarized below and described in detail in the table  (<a class="graphic graphic_table graphicRef118014" href="/d/graphic/118014.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For adults and children ≥8 years of age, we suggest <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> plus <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children &lt;8 years of age and those unable to take <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, we administer <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> <strong>plus</strong> either <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with neuroretinitis, we treat for four to six weeks. For patients with Parinaud oculoglandular disease or other neurologic involvement (including encephalitis), we treat for 10 to 14 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional considerations for patients with neuroretinitis and young children with severe disease are discussed below. (See <a class="local">'Neuroretinitis'</a> below and <a class="local">'Young children with severe disease'</a> below.)</p><p></p><p>In general, we prefer the combination of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> plus <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> because there is the most experience with this combination. As an example, a retrospective case series of seven consecutive patients with <em>B. henselae</em> neuroretinitis evaluated the outcome of patients treated with doxycycline (100 mg orally twice daily) and rifampin (300 mg orally twice daily) for four to six weeks compared with historic controls [<a href="#rid20">20</a>]. Antibiotic therapy appeared to promote the resolution of retinitis. In addition, there is extensive clinical experience with the use of doxycycline for treating central nervous system infections caused by other pathogens. </p><p class="headingAnchor" id="H2192336968"><span class="h2">Additional considerations</span></p><p class="headingAnchor" id="H9"><span class="h3">Neuroretinitis</span><span class="headingEndMark"> — </span>For patients with neuroretinitis, we suggest adjunctive corticosteroids in addition to antimicrobial therapy. Such patients should be monitored closely by an ophthalmologist. </p><p>The optimal corticosteroid regimen is unknown. We administer a six-week course of corticosteroids using 1 mg/kg of oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> for two weeks with a gradual taper over the following four weeks.</p><p>Although data are limited, the use of corticosteroids for neuroretinitis was supported in a multicenter, retrospective cohort study of 86 patients with ocular manifestations of CSD (eg, neuroretinitis, inflammatory disc edema, uveitis, or vascular occlusions) [<a href="#rid8">8</a>]. Visual improvement at follow-up was significantly better in patients who received corticosteroids plus antimicrobials versus those who were treated with antimicrobial therapy alone (88 versus 50 percent). In this study, most of the patients were adults with neuroretinitis and most received oral <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> plus <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>; corticosteroids were usually administered as oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at a mean starting dose of 40 to 80 mg/day and tapered gradually for a total treatment duration of six weeks. </p><p class="headingAnchor" id="H3430601294"><span class="h3">Young children with severe disease</span><span class="headingEndMark"> — </span>In general, we avoid <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> in children &lt;8 years old because of concerns of dental staining. However, in patients with sight-threatening neuroretinitis or severe neurologic disease, the following key points related to the risks and benefits of doxycycline should be considered and discussed. </p><p class="bulletIndent1"><span class="glyph">●</span>Although there are very limited data on the optimal treatment regimen for neurologic and ocular disease, most studies evaluating the treatment of neuroretinitis have used <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> in combination with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>. In addition, there is extensive clinical experience with the use of doxycycline to treat central nervous system infections caused by other pathogens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Observational studies support the relative safety of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> compared with older tetracyclines when short courses are administered to children; however, the impact of longer durations is unknown. </p><p></p><p>Thus, the choice of antimicrobial regimen for young children with severe ocular or neurologic disease must be determined on a case-by-case basis. </p><p class="headingAnchor" id="H11"><span class="h1">ENDOCARDITIS</span><span class="headingEndMark"> — </span>Treatment of suspected or proven <em>Bartonella</em> endocarditis is discussed separately. (See  <a class="medical medical_review" href="/d/html/2145.html" rel="external">"Endocarditis caused by Bartonella"</a>.)</p><p class="headingAnchor" id="H149135197"><span class="h1">ROLE OF CORTICOSTEROIDS</span><span class="headingEndMark"> — </span>We suggest administering adjunctive corticosteroids to patients with neuroretinitis. The use of corticosteroids in this setting is discussed above. (See <a class="local">'Neuroretinitis'</a> above.)</p><p>On rare occasion, adjunctive corticosteroids may also be reasonable for patients with severe or persistent disease other than neuroretinitis. For such patients, an initial dose of 1 mg/kg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (maximum daily dose 80 mg/day) can be administered for five to seven days, with a taper over the subsequent 10 to 14 days. </p><p>The use of corticosteroids in patients without neuroretinitis is based upon expert opinion since there are no controlled trials examining their efficacy in patients with CSD. The rationale for their use is based in part upon the observation that, despite an intense inflammatory response, there are very few organisms detected in the lymphoid tissue of patients with classic CSD or in the granulomatous material of patients with hepatosplenic involvement [<a href="#rid9">9,21</a>]. In addition, multiple case reports have described rapid resolution of localized and systemic symptoms following a course of corticosteroids, including reports in patients with hepatosplenic CSD [<a href="#rid22">22-25</a>]. These reports included patients who had progressive and/or persistent disease despite receiving antimicrobial therapy. Further study is needed to determine if corticosteroids should have a role in the management of CSD, and if so, what dose would provide optimal benefit. </p><p class="headingAnchor" id="H3834063"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83675.html" rel="external">"Patient education: Cat scratch disease (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical overview</strong> – Cat scratch disease (CSD) is an infectious disease cause by <em>Bartonella</em> <em>henselae </em>and is usually characterized by self-limited regional lymphadenopathy. However, the manifestations can include visceral organ, neurologic, and ocular involvement. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to antimicrobial therapy</strong> – We suggest antimicrobial treatment for all patients with CSD (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This includes immunocompetent patients with mild to moderate lymphadenitis. Although some patients may improve without therapy, treatment may shorten the duration of symptoms and reduce the risk of developing systemic disease and/or long-term sequelae. The approach to treatment of CSD primarily derives from case reports, small series, and personal experience. (See <a class="local">'Approach to treatment'</a> above and <a class="local">'Whom to treat'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphadenitis</strong> – For patients with lymphadenitis as the only manifestation, we suggest <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>  (<a class="graphic graphic_table graphicRef118014" href="/d/graphic/118014.html" rel="external">table 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternative regimens include <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and, in adults, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>. Repeat treatment (with azithromycin plus rifampin) and adjunctive therapies, such as needle aspiration and corticosteroids, may be warranted in severe or refractory cases. (See <a class="local">'Lymphadenitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serious infections other than lymphadenitis</strong> – For those with more serious infections, we suggest combination therapy that includes <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The duration of treatment and the use of adjunctive corticosteroids depends upon the clinical manifestation  (<a class="graphic graphic_table graphicRef118014" href="/d/graphic/118014.html" rel="external">table 1</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hepatosplenic disease or fever of unknown origin</strong> – For these patients, we administer <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> plus <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>. Alternative regimens include rifampin plus <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> or higher doses of azithromycin alone (for adults). (See <a class="local">'Hepatosplenic disease/fever of unknown origin'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Neurologic or ocular disease</strong> – For adults and children ≥8 years of age with neurologic or ocular disease, we administer <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> plus <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>. In children &lt;8 years of age, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> or <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> should generally be substituted for doxycycline; however, for those with severe disease, the risks and benefits of using doxycycline should be discussed. (See <a class="local">'Neurologic and ocular manifestations'</a> above and <a class="local">'Young children with severe disease'</a> above.)</p><p></p><p class="bulletIndent3">For patients with neuroretinitis, the usual duration of antimicrobial therapy is four to six weeks; such patients should be managed in conjunction with an ophthalmologist. The duration of treatment for patients with Parinaud oculoglandular disease and other neurologic manifestations is 10 to 14 days. (See <a class="local">'Preferred regimens'</a> above and <a class="local">'Neuroretinitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of corticosteroids</strong> – For patients with neuroretinitis, we suggest adjunctive corticosteroids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). On rare occasion, it may also be reasonable to administer corticosteroids to patients with severe or persistent disease other than neuroretinitis. (See <a class="local">'Role of corticosteroids'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bass JW, Vincent JM, Person DA. The expanding spectrum of Bartonella infections: II. Cat-scratch disease. Pediatr Infect Dis J 1997; 16:163.</a></li><li><a class="nounderline abstract_t">Spach DH, Koehler JE. Bartonella-associated infections. Infect Dis Clin North Am 1998; 12:137.</a></li><li><a class="nounderline abstract_t">Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother 2004; 48:1921.</a></li><li><a class="nounderline abstract_t">Prutsky G, Domecq JP, Mori L, et al. Treatment outcomes of human bartonellosis: a systematic review and meta-analysis. Int J Infect Dis 2013; 17:e811.</a></li><li><a class="nounderline abstract_t">Angelakis E, Raoult D. Pathogenicity and treatment of Bartonella infections. Int J Antimicrob Agents 2014; 44:16.</a></li><li><a class="nounderline abstract_t">Carithers HA. Cat-scratch disease. An overview based on a study of 1,200 patients. Am J Dis Child 1985; 139:1124.</a></li><li><a class="nounderline abstract_t">Margileth AM. Cat scratch disease. Adv Pediatr Infect Dis 1993; 8:1.</a></li><li><a class="nounderline abstract_t">Habot-Wilner Z, Trivizki O, Goldstein M, et al. Cat-scratch disease: ocular manifestations and treatment outcome. Acta Ophthalmol 2018; 96:e524.</a></li><li><a class="nounderline abstract_t">Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J 1992; 11:474.</a></li><li><a class="nounderline abstract_t">Bass JW, Freitas BC, Freitas AD, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 1998; 17:447.</a></li><li class="breakAll">American Academy of Pediatrics. Bartonella henselae (Cat-Scratch Disease). In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca IL 2021. p.831.</li><li><a class="nounderline abstract_t">Collio PJ. Cat-scratch disease: therapy with trimethoprim-sulfamethoxazole. Am J Dis Child 1992; 146:397.</a></li><li><a class="nounderline abstract_t">Shorbatli LA, Koranyi KI, Nahata MC. Effectiveness of antibiotic therapy in pediatric patients with cat scratch disease. Int J Clin Pharm 2018; 40:1458.</a></li><li><a class="nounderline abstract_t">Holley HP Jr. Successful treatment of cat-scratch disease with ciprofloxacin. JAMA 1991; 265:1563.</a></li><li><a class="nounderline abstract_t">King KY, Hicks MJ, Mazziotti MV, et al. Persistent cat scratch disease requiring surgical excision in a patient with MPGN. Pediatrics 2015; 135:e1514.</a></li><li><a class="nounderline abstract_t">Arisoy ES, Correa AG, Wagner ML, Kaplan SL. Hepatosplenic cat-scratch disease in children: selected clinical features and treatment. Clin Infect Dis 1999; 28:778.</a></li><li><a class="nounderline abstract_t">Bogue CW, Wise JD, Gray GF, Edwards KM. Antibiotic therapy for cat-scratch disease? JAMA 1989; 262:813.</a></li><li><a class="nounderline abstract_t">García JC, Núñez MJ, Castro B, et al. Hepatosplenic cat scratch disease in immunocompetent adults: report of 3 cases and review of the literature. Medicine (Baltimore) 2014; 93:267.</a></li><li><a class="nounderline abstract_t">Rosen BS, Barry CJ, Nicoll AM, Constable IJ. Conservative management of documented neuroretinitis in cat scratch disease associated with Bartonella henselae infection. Aust N Z J Ophthalmol 1999; 27:153.</a></li><li><a class="nounderline abstract_t">Reed JB, Scales DK, Wong MT, et al. Bartonella henselae neuroretinitis in cat scratch disease. Diagnosis, management, and sequelae. Ophthalmology 1998; 105:459.</a></li><li><a class="nounderline abstract_t">Florin TA, Zaoutis TE, Zaoutis LB. Beyond cat scratch disease: widening spectrum of Bartonella henselae infection. Pediatrics 2008; 121:e1413.</a></li><li><a class="nounderline abstract_t">ECKHARDT WF Jr, LEVINE AI. Corticosteroid therapy of cat-scratch disease. Results of treatment in three cases with rapid resolution of painful lymphadenopathy; Tietze's syndrome and bilateral cervical adenitis as new complications. Arch Intern Med 1962; 109:463.</a></li><li><a class="nounderline abstract_t">Lerdluedeeporn P, Krogstad P, Roberts RL, Stiehm ER. Oral corticosteroids in cat-scratch disease. Clin Pediatr (Phila) 2003; 42:71.</a></li><li><a class="nounderline abstract_t">Bryant K, Marshall GS. Hepatosplenic cat scratch disease treated with corticosteroids. Arch Dis Child 2003; 88:345.</a></li><li><a class="nounderline abstract_t">Phan A, Castagnini LA. Corticosteroid Treatment for Prolonged Fever in Hepatosplenic Cat-Scratch Disease: A Case Study. Clin Pediatr (Phila) 2017; 56:1291.</a></li></ol></div><div id="topicVersionRevision">Topic 5530 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9041596" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The expanding spectrum of Bartonella infections: II. Cat-scratch disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9494835" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Bartonella-associated infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15155180" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Recommendations for treatment of human infections caused by Bartonella species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602630" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment outcomes of human bartonellosis: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24933445" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pathogenicity and treatment of Bartonella infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4061408" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cat-scratch disease. An overview based on a study of 1,200 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8216999" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cat scratch disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29504674" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cat-scratch disease: ocular manifestations and treatment outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1608685" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9655532" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9655532" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558070" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cat-scratch disease: therapy with trimethoprim-sulfamethoxazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30446895" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effectiveness of antibiotic therapy in pediatric patients with cat scratch disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1999905" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Successful treatment of cat-scratch disease with ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25963015" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Persistent cat scratch disease requiring surgical excision in a patient with MPGN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10825038" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hepatosplenic cat-scratch disease in children: selected clinical features and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2746837" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antibiotic therapy for cat-scratch disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25398062" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hepatosplenic cat scratch disease in immunocompetent adults: report of 3 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10379716" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Conservative management of documented neuroretinitis in cat scratch disease associated with Bartonella henselae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9499776" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bartonella henselae neuroretinitis in cat scratch disease. Diagnosis, management, and sequelae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443019" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Beyond cat scratch disease: widening spectrum of Bartonella henselae infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13889108" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Corticosteroid therapy of cat-scratch disease. Results of treatment in three cases with rapid resolution of painful lymphadenopathy; Tietze's syndrome and bilateral cervical adenitis as new complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12635985" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Oral corticosteroids in cat-scratch disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12651767" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hepatosplenic cat scratch disease treated with corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28006985" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Corticosteroid Treatment for Prolonged Fever in Hepatosplenic Cat-Scratch Disease: A Case Study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
